NCT05876039View on ClinicalTrials.gov

Optimal Dosage of Remifentanil for Vertebroplasty

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 20, 2023

Primary Completion Date

August 24, 2024

Study Completion Date

December 27, 2024

Conditions
RemifentanilAnalgesia
Interventions
DRUG

Initial remifentanil effect-site concentration

Different initial remifentanil effect-site concentration

Trial Locations (1)

114

Tri-Service General Hospital, Taipei

All Listed Sponsors
lead

Tri-Service General Hospital

OTHER

NCT05876039 - Optimal Dosage of Remifentanil for Vertebroplasty | Biotech Hunter | Biotech Hunter